Tumor Metastasis: Fishing for drugs
About 90% of all cancer-related deaths are caused by metastasis, which is when cancer cells spread to other parts of the body to form new tumors (Chaffer and Weinberg, 2011; Suhail et al., 2019). Yet, the majority of currently available therapeutics do not inhibit metastasis, and only target the primary tumor where the cancer initially arises from.
To screen anti-cancer drugs, researchers often carry out experiments on mice or cells grown in the laboratory. While these model systems have led to effective treatments, they have limitations when it comes to testing drugs that block metastasis. For instance, cells cultured in the laboratory cannot accurately replicate tumor progression in humans (Katt et al., 2016), and metastasis can take at least several weeks to appear in mouse models, which are expensive to create and maintain (Simons and Brayton, 2017). Now, in eLife, Joji Nakayama, Zhiyuan Gong and co-workers report an innovative zebrafish model for screening anti-metastasis drugs (Nakayama et al., 2021).
The zebrafish was introduced to the research field in 1972, and has become a powerful model system for cancer research, due to its relative transparency, high reproduction rates, and genetic similarity to humans (Brown et al., 2017; Chen et al., 2021; Fazio et al., 2020; Gamble et al., 2021; Hason and Bartůněk, 2019). Early in development, cells in the zebrafish embryo undergo a morphological change and migrate inwards via a process called epiboly (Bruce and Heisenberg, 2020). The way these healthy cells move is similar to how cancer cells travel across tissues during metastasis. Hence, Nakayama et al. proposed that small-molecule inhibitors that interrupt epiboly may also suppress metastasis.
The team (who are based at the National University of Singapore, the National Cancer Center in Japan and other institutes in Singapore and Japan) found that some of the genes expressed during zebrafish epiboly are also activated during tumor metastasis. This finding provides the experimental support that zebrafish epiboly can serve as a model for tumor cell movement. So, Nakayama et al. developed a zebrafish screening platform, which they used to test 1,280 drugs that had already been approved by a government agency, such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
The screen was carried out on zebrafish embryos exposed to a specific drug at four hours post-fertilization (Figure 1A). Nakayama et al. found that 132 of the drugs tested induced a delay in epiboly after five hours of treatment. Several of these drugs had previously been reported to inhibit molecular mechanisms associated with metastasis (Liu et al., 2013; Nakayama et al., 2020).
Nakayama et al. then used cell-based assays to test whether 62 of these 132 ‘positive hits’ (which also delay epiboly in vitro) can suppress the migration of cancer cells (Figure 1B). The tumor cells were placed in a chamber with or without the drug, and the team recorded how many could crawl into the neighboring compartment after a few hours of treatment. This revealed that 20 of the drugs that disrupted epiboly also impeded the movement of human cancer cells.
Finally, Nakayama et al. tested if one of the epiboly-interrupting drugs called Pizotifen could also impair tumor cell movement in living animals: this drug was selected because its primary target (serotonin receptor 2C) is highly expressed in human cancer cells during metastasis. To do this, they injected fluorescently labelled cancer cells into zebrafish embryos, and found that fish exposed to Pizotifen experienced significantly less metastasis than fish treated with a placebo. Similar observations were made in mice that had cancer cells injected into their breast-like tissue, half of which were treated with a daily dose of Pizotifen, and half of which received a placebo (Figure 1B).
The screening platform created by Nakayama et al. makes it easy to rapidly find new drugs that suppress metastasis, while circumventing the limitations of cell culture and mouse model systems. In addition, zebrafish injected with human cancer cells can serve as an additional means for narrowing down which drugs to test in mouse models. Having zebrafish join the drug discovery platform will hopefully result in more and better treatments for patients with metastatic cancers.
References
-
Zebrafish xenograft models of cancer and metastasis for drug discoveryExpert Opinion on Drug Discovery 12:379–389.https://doi.org/10.1080/17460441.2017.1297416
-
Mechanisms of zebrafish epiboly: a current viewCurrent Topics in Developmental Biology 136:319–341.https://doi.org/10.1016/bs.ctdb.2019.07.001
-
A perspective on cancer cell metastasisScience 331:1559–1564.https://doi.org/10.1126/science.1203543
-
Benefits of zebrafish xenograft models in cancer researchFrontiers in Cell and Developmental Biology 9:616551.https://doi.org/10.3389/fcell.2021.616551
-
Zebrafish patient avatars in cancer biology and precision cancer therapyNature Reviews Cancer 20:263–273.https://doi.org/10.1038/s41568-020-0252-3
-
In vitro tumor models: advantages, disadvantages, variables, and selecting the right platformFrontiers in Bioengineering and Biotechnology 4:12.https://doi.org/10.3389/fbioe.2016.00012
-
BookChapter 3 - Challenges and Limitations of Mouse Xenograft Models of CancerIn: Simons BW, editors. Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Academic Press. pp. 25–36.https://doi.org/10.1016/B978-0-12-804010-2.00003-5
-
Systems biology of cancer metastasisCell Systems 9:109–127.https://doi.org/10.1016/j.cels.2019.07.003
Article and author information
Author details
Acknowledgements
HF acknowledges grants from the National Institutes of Health (NIH; CA215059), the American Cancer Society (RSG-17-204-01-TBG), the National Science Foundation (1911253), and Boston University; CK thanks the diversity grant support from the National Institutes of Health (NIH; CA215059S); and EH is grateful for the Undergraduate Research of Program Award from Boston University.
Publication history
Copyright
© 2022, Kemet et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 979
- views
-
- 96
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Chromosomes and Gene Expression
- Developmental Biology
Differentiation of female germline stem cells into a mature oocyte includes the expression of RNAs and proteins that drive early embryonic development in Drosophila. We have little insight into what activates the expression of these maternal factors. One candidate is the zinc-finger protein OVO. OVO is required for female germline viability and has been shown to positively regulate its own expression, as well as a downstream target, ovarian tumor, by binding to the transcriptional start site (TSS). To find additional OVO targets in the female germline and further elucidate OVO’s role in oocyte development, we performed ChIP-seq to determine genome-wide OVO occupancy, as well as RNA-seq comparing hypomorphic and wild type rescue ovo alleles. OVO preferentially binds in close proximity to target TSSs genome-wide, is associated with open chromatin, transcriptionally active histone marks, and OVO-dependent expression. Motif enrichment analysis on OVO ChIP peaks identified a 5’-TAACNGT-3’ OVO DNA binding motif spatially enriched near TSSs. However, the OVO DNA binding motif does not exhibit precise motif spacing relative to the TSS characteristic of RNA polymerase II complex binding core promoter elements. Integrated genomics analysis showed that 525 genes that are bound and increase in expression downstream of OVO are known to be essential maternally expressed genes. These include genes involved in anterior/posterior/germ plasm specification (bcd, exu, swa, osk, nos, aub, pgc, gcl), egg activation (png, plu, gnu, wisp, C(3)g, mtrm), translational regulation (cup, orb, bru1, me31B), and vitelline membrane formation (fs(1)N, fs(1)M3, clos). This suggests that OVO is a master transcriptional regulator of oocyte development and is responsible for the expression of structural components of the egg as well as maternally provided RNAs that are required for early embryonic development.
-
- Developmental Biology
Over the past several decades, a trend toward delayed childbirth has led to increases in parental age at the time of conception. Sperm epigenome undergoes age-dependent changes increasing risks of adverse conditions in offspring conceived by fathers of advanced age. The mechanism(s) linking paternal age with epigenetic changes in sperm remain unknown. The sperm epigenome is shaped in a compartment protected by the blood-testes barrier (BTB) known to deteriorate with age. Permeability of the BTB is regulated by the balance of two mTOR complexes in Sertoli cells where mTOR complex 1 (mTORC1) promotes the opening of the BTB and mTOR complex 2 (mTORC2) promotes its integrity. We hypothesized that this balance is also responsible for age-dependent changes in the sperm epigenome. To test this hypothesis, we analyzed reproductive outcomes, including sperm DNA methylation in transgenic mice with Sertoli cell-specific suppression of mTORC1 (Rptor KO) or mTORC2 (Rictor KO). mTORC2 suppression accelerated aging of the sperm DNA methylome and resulted in a reproductive phenotype concordant with older age, including decreased testes weight and sperm counts, and increased percent of morphologically abnormal spermatozoa and mitochondrial DNA copy number. Suppression of mTORC1 resulted in the shift of DNA methylome in sperm opposite to the shift associated with physiological aging – sperm DNA methylome rejuvenation and mild changes in sperm parameters. These results demonstrate for the first time that the balance of mTOR complexes in Sertoli cells regulates the rate of sperm epigenetic aging. Thus, mTOR pathway in Sertoli cells may be used as a novel target of therapeutic interventions to rejuvenate the sperm epigenome in advanced-age fathers.